title: Clinical characteristics and prognostic factors of prostate cancer with liver metastases.
abstract: Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29%. Eight (29.63%) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37%) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.
authors: HaiTao
authors: H
authors: Wang
authors: BaoGuo
authors: B
authors: Li
authors: PengYu
authors: P
authors: Zhang
authors: YanHong
authors: Y
authors: Yao
authors: JiWu
authors: J
authors: Chang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D016896:Treatment Outcome
references: Urol Clin North Am. 1984 May;11(2):205-20
references: 6375067
references: Cancer. 1981 Jan 1;47(1):207-14
references: 7459811
references: Endocr Relat Cancer. 2005 Mar;12(1):109-17
references: 15788643
references: J Neurooncol. 2012 Mar;107(1):191-6
references: 21989810
references: Cancer. 2000 Jun 1;88(11):2590-7
references: 10861438
references: Cancer Lett. 2012 Feb 28;315(2):170-7
references: 22099876
references: Ann Oncol. 2010 Jun;21(6):1323-1360
references: 19948741
references: N Engl J Med. 2011 May 26;364(21):1995-2005
references: 21612468
references: N Engl J Med. 1998 Oct 8;339(15):1036-42
references: 9761805
references: Bull Cancer. 2010 Jan;97(1):47-54
references: 19995688
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: BJU Int. 2007 Apr;99(4):807-11
references: 17155968
references: Oncol Lett. 2013 Jun;5(6):1877-1880
references: 23833660
references: Ann Oncol. 2012 Nov;23(11):2943-2947
references: 22771826